Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11952367 Pyridine and pyridimine compounds as PI3K-gamma inhibitors

Patent 11952367 was granted and assigned to Incyte on April, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Andrew W. Buesking0

Lixin Shao0

Haisheng Wang0

Stacey Shepard0

Richard B. Sparks0

Nikoo Falahatpisheh0

Andrew P. Combs0

Date of Patent

April 9, 2024

0

Patent Application Number

177050790

Date Filed

March 25, 2022

0

Patent Citations

US Patent 8759359 Substituted heteroaryl fused derivatives as PI3K inhibitors

0

US Patent 7186832 Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors

0

US Patent 7511145 Bicyclic heteroaryl derivatives

0

US Patent 8680108 Substituted fused aryl and heteroaryl derivatives as PI3K inhibitors

0

US Patent 8940752 Pyrimidinones as PI3K inhibitors

0

US Patent 9062055 Fused pyrrole derivatives as PI3K inhibitors

0

US Patent 9096600 N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors

0

US Patent 9108984 Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors

0

...

Patent Primary Examiner

D Margaret M Seaman

0

CPC Code

0

0

0

0

0

0

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11952367 Pyridine and pyridimine compounds as PI3K-gamma inhibitors

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool